DCM
HAE icon

Diag Capital Management’s Haemonetics HAE Stock Holding History

Diag Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$2.12M Buy
+21,220
New +$2.23M 2.43% 21

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Diag Capital Management's HAE Position: Q4 2018 in Review

Diag Capital Management opened a new position in Haemonetics (HAE) in Q4 2018: 21,220 shares worth $2.12M. The stake represents 2.43% of the portfolio and ranks #21 among its holdings.

279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Diag Capital Management held 21,220 shares of Haemonetics worth $2.12M as of Q4 2018.
  • Haemonetics was a new Diag Capital Management position in Q4 2018.
  • Haemonetics made up 2.43% of Diag Capital Management's portfolio in Q4 2018, its #21 holding.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.